OasisLMS

In this session, Dr. Andrew Wang, Professor at Duke University, reviews how to assess and prevent sudden cardiac death in patients with hypertrophic cardiomyopathy (HCM). He walks through the 2024 AHA/ACC guideline recommendations, including major risk factors such as massive LV hypertrophy, unexplained syncope, family history of sudden death, apical aneurysm, and reduced ejection fraction. He also covers the role of risk modifiers like non-sustained VT and late gadolinium enhancement on cardiac MRI, how to use the five-year SCD risk calculator, and why shared decision making is central when considering a primary prevention ICD.

Made possible with support from Medtronic

• Identify the major risk factors for sudden cardiac death in HCM as defined by the 2024 AHA/ACC guidelines.
• Apply the five-year HCM SCD risk calculator to support patient counseling and shared decision making.
• Describe how non-sustained VT and late gadolinium enhancement on cardiac MRI help refine a patient's overall risk.
• Distinguish between secondary and primary prevention ICD recommendations in patients with HCM.
• Explain the importance of reassessing SCD risk every one to two years and involving patients in ICD decisions.

Presenter

Andrew Wang, MD, FACC, FAHA
Duke University Medical Center  | Director of Cardiovascular Medicine